Why VERAXA Biotech AG (NASDAQ: VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals
Deal activity remains strong in antibody-drug conjugates (ADCs) and T-cell engager (TCE) therapeutics, with pharmaceutical companies continuing to commit substantial…